Literature DB >> 32742200

Definitive single fraction stereotactic ablative radiotherapy for inoperable early-stage breast cancer: A case report.

Manasa Veluvolu1, Mausam Patel1, Ganesh Narayanasamy1, Thomas Kim2.   

Abstract

We review a case of inoperable early stage breast cancer treated definitively with the use of stereotactic ablative radiotherapy (SABR). A 57-year-old female with a history of decompensated cirrhosis with early stage breast cancer was treated with 25 Gy in one fraction. At her 7-month follow up visit, there was a complete resolution of disease on imaging. This case represents a novel approach for the treatment of breast cancer with SABR when surgery is contraindicated.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast; Case; Definitive; SABR; SBRT

Year:  2020        PMID： 32742200      PMCID： PMC7387738          DOI： 10.1016/j.rpor.2020.06.011

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  19 in total

1.  An overview of hypofractionation and introduction to this issue of seminars in radiation oncology.

Authors:  Robert D Timmerman
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

Review 2.  New Techniques for Irradiating Early Stage Breast Cancer: Stereotactic Partial Breast Irradiation.

Authors:  Asal Rahimi; Robert Timmerman
Journal:  Semin Radiat Oncol       Date:  2017-02-20       Impact factor: 5.934

3.  Durable response of early-stage breast cancer to bilateral definitive SBRT in a medically inoperable patient.

Authors:  Robert W Gao; Sean S Park; James W Jakub; Tina J Hieken; Amy L Conners; Lonzetta Neal; Sandhya Pruthi; Kimberly S Corbin; Elizabeth S Yan; Robert W Mutter; Bradley J Stish
Journal:  Pract Radiat Oncol       Date:  2018-03-18

4.  Stereotactic body radiation therapy vs. surgery in early-stage non-small cell lung cancer: lessons learned, current recommendations, future directions.

Authors:  Sibo Tian; Kristin A Higgins; Walter J Curran; Richard J Cassidy
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Local control of operable breast cancer after radiotherapy alone.

Authors:  E Van Limbergen; E Van der Schueren; W Van den Bogaert; J Van Wing
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital.

Authors:  R Arriagada; H Mouriesse; D Sarrazin; R M Clark; G Deboer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-10       Impact factor: 7.038

Review 7.  Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery?

Authors:  Shervin M Shirvani; Joe Y Chang; Jack A Roth
Journal:  Thorac Surg Clin       Date:  2013-08       Impact factor: 1.750

Review 8.  Accelerated Partial Breast Irradiation in Clinical Practice.

Authors:  Frederik Wenz; Felix Sedlmayer; Carsten Herskind; Grit Welzel; Elena Sperk; Christian Neumaier; Benjamin Gauter-Fleckenstein; Jayant S Vaidya; Marc Sütterlin
Journal:  Breast Care (Basel)       Date:  2015-07-15       Impact factor: 2.860

9.  Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.

Authors:  Steven David; Jennifer Tan; Peter Savas; Mathias Bressel; Dianne Kelly; Farshad Foroudi; Sherene Loi; Shankar Siva
Journal:  Breast       Date:  2019-11-06       Impact factor: 4.380

10.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

Authors:  S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold
Journal:  Lancet Oncol       Date:  2008-03-19       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.